Adial Pharmaceuticals Inc
$ 3.03
-1.94%
10 Feb - close price
- Market Cap 3,366,800 USD
- Current Price $ 3.03
- High / Low $ 3.16 / 2.86
- Stock P/E N/A
- Book Value 4.72
- EPS -14.88
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.79 %
- ROE -1.55 %
- 52 Week High 32.50
- 52 Week Low 2.86
About
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Charlottesville, Virginia, dedicated to developing innovative therapies for substance use disorders, with a particular focus on alcohol use disorder. The company's lead candidate, AD04, is designed to tackle critical health challenges in this underserved market, underscoring Adial's commitment to enhancing patient outcomes. With a strong development pipeline and a strategic vision for transforming addiction treatment and prevention, Adial is poised to make a significant impact on public health and the lives of individuals grappling with addiction.
Analyst Target Price
$54.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-13 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-05-14 | 2024-02-20 | 2023-11-14 | 2023-08-21 | 2023-05-12 | 2023-03-30 |
| Reported EPS | -0.08 | -0.18 | -0.34 | -0.15 | -0.38 | -0.59 | -0.62 | -1.35 | -1.18 | 0.96 | -0.11 | -0.105 |
| Estimated EPS | -0.39 | -0.39 | -0.495 | -0.33 | -0.44 | -0.53 | -0.33 | -0.76 | -1.13 | -1.5 | -0.14 | -0.15 |
| Surprise | 0.31 | 0.21 | 0.155 | 0.18 | 0.06 | -0.06 | -0.29 | -0.59 | -0.05 | 2.46 | 0.03 | 0.045 |
| Surprise Percentage | 79.4872% | 53.8462% | 31.3131% | 54.5455% | 13.6364% | -11.3208% | -87.8788% | -77.6316% | -4.4248% | 164% | 21.4286% | 30% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADIL
2026-02-04 23:28:43
Adial Pharmaceuticals Inc. (NASDAQ: ADIL) stock fell significantly in after-hours trading after announcing a 1-for-25 reverse stock split scheduled for February 5, 2026. This move is primarily aimed at complying with Nasdaq's minimum bid price requirement of $1.00 per share. The company stated the split will reduce outstanding shares and enhance its capital markets profile for institutional investors.
2026-02-04 22:58:56
Adial Pharmaceuticals, a biopharmaceutical company, supports a new congressional directive for the FDA and NIDA to establish alternative clinical trial endpoints for substance use disorders, moving beyond traditional abstinence measures. This directive, included in the 2026 Appropriations Bill, aims to incorporate outcomes like reduced cravings and disorder severity, aligning with Adial's precision medicine approach for its lead therapy, AD04, which treats Alcohol Use Disorder. The company believes these changes will enhance the regulatory pathway for innovative treatments and address significant public health challenges.
2026-02-04 21:27:51
Adial Pharmaceuticals Inc. praised a new Congressional directive that mandates the FDA and NIDA collaborate on establishing alternative clinical trial endpoints for substance use disorders, including Alcohol Use Disorder (AUD). This directive, which includes considering reduced cravings and disorder severity as meaningful clinical benefits, aligns with Adial's lead investigational therapy, AD04. The company believes this move will modernize regulatory expectations, accelerate development timelines for therapies, and strengthen the regulatory path for AD04.
2026-02-04 21:05:00
Adial Pharmaceuticals is implementing a 1-for-25 reverse stock split, effective February 5, 2026, to bring its stock price into compliance with Nasdaq's minimum bid price requirement. This measure aims to strengthen the company's capital markets profile, attract more institutional and retail investors, and support its strategic priorities, including the advancement of its lead drug AD04 for Alcohol Use Disorder. The reverse split will reduce the number of outstanding shares and proportionally adjust equity awards, while not changing the total authorized shares.
2026-02-04 20:28:23
Adial Pharmaceuticals (ADIL) will implement a 1-for-25 reverse stock split on February 5, 2026, reducing its outstanding shares and causing a significant drop in its stock price after hours. The company is also advocating for the FDA to develop new clinical trial endpoints for substance use disorder treatments, which would facilitate the regulatory approval process for its alcohol use disorder therapy, AD04.
2026-02-04 14:28:23
Adial Pharmaceuticals announced that Congress has included a directive in the federal appropriations bill for the FDA and NIDA to collaborate on alternative clinical trial endpoints for substance use disorders (SUDs), including non-abstinence measures like reduced cravings. This directive is expected to strengthen the regulatory pathway for Adial's lead investigational therapy, AD04, which targets Alcohol Use Disorder (AUD) using a precision medicine approach. The company believes this modernization of regulatory expectations will support innovation and address the unmet need in AUD treatment.
